In the trial, 26 patients with solid tumors, including 12 melanomas, 1 NSCLC, and 13 renal cell carcinomas, who had progressed on anti-PD-1/PD-L1 treatment, were treated in dose-escalating cohorts of APX005M with fixed doses of cabiralizumab, with or without nivolumab. The gene discussed is CD274; the disease is non-small cell lung carcinoma.